RXRX
RecursionFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Composite grade F from latest DB weights. Momentum 14.3 / Value 41.1
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
14
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.25
Why
Momentum14 · Δ7d -6.8
Value41 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
14
40% active weight
Current posture
7d trendSoftening
Δ7d
-6.8
Δ21d
-12.8
Value
41
60% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 14.3 / Value 41.1
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.63B
Beta
0.94
Shares Out
530.76M
P/E (TTM) · Derived
-2.1
P/S (TTM)
52.00
P/FCF (TTM) · Derived
-4.42
Rev YoY
-56.1%
EPS YoY
-55.8%
Gross Margin
-69.6%
Op Margin
-1678.4%
Net Debt
-$669.92M
Current Ratio
5.47
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology

